Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians
Alassane Dicko, David J Diemert, Issaka Sagara, Moussa Sogoba, Mohamed B Niambele, Mahamadoun H Assadou, Ousmane Guindo, Beh Kamate, Mounirou Baby, Mady Sissoko, Elissa M Malkin, Michael P Fay, Mahamadou A Thera, Kazutoyo Miura, Amagana Dolo, Dapa A Diallo, Gregory E Mullen, Carole A Long, Allan Saul, Ogobara Doumbo, Louis H Miller, Alassane Dicko, David J Diemert, Issaka Sagara, Moussa Sogoba, Mohamed B Niambele, Mahamadoun H Assadou, Ousmane Guindo, Beh Kamate, Mounirou Baby, Mady Sissoko, Elissa M Malkin, Michael P Fay, Mahamadou A Thera, Kazutoyo Miura, Amagana Dolo, Dapa A Diallo, Gregory E Mullen, Carole A Long, Allan Saul, Ogobara Doumbo, Louis H Miller
Abstract
Background: Apical Membrane Antigen 1 (AMA1) of Plasmodium falciparum merozoites is a leading blood-stage malaria vaccine candidate. Protection of Aotus monkeys after vaccination with AMA1 correlates with antibody responses.
Study design/results: A randomized, controlled, double-blind phase 1 clinical trial was conducted in 54 healthy Malian adults living in an area of intense seasonal malaria transmission to assess the safety and immunogenicity of the AMA1-C1 malaria vaccine. AMA1-C1 contains an equal mixture of yeast-expressed recombinant proteins based on sequences from the FVO and 3D7 clones of P. falciparum, adsorbed on Alhydrogel. The control vaccine was the hepatitis B vaccine (Recombivax). Participants were enrolled into 1 of 3 dose cohorts (n = 18 per cohort) and randomized 2:1 to receive either AMA1-C1 or Recombivax. Participants in the first, second, and third cohorts randomized to receive AMA1-C1 were vaccinated with 5, 20 and 80 microg of AMA1-C1, respectively. Vaccinations were administered on days 0, 28, and 360, and participants were followed until 6 months after the final vaccination. AMA1-C1 was well tolerated; no vaccine-related severe or serious adverse events were observed. AMA1 antibody responses to the 80 microg dose increased rapidly from baseline levels by days 14 and 28 after the first vaccination and continued to increase after the second vaccination. After a peak 14 days following the second vaccination, antibody levels decreased to baseline levels one year later at the time of the third vaccination that induced little or no increase in antibody levels.
Conclusions: Although the AMA1-C1 vaccine candidate was well-tolerated and induced antibody responses to both vaccine and non-vaccine alleles, the antibody response after a third dose given at one year was lower than the response to the initial vaccinations. Additionally, post-vaccination increases in anti-AMA1 antibody levels were not associated with significant changes in in vitro growth inhibition of P. falciparum.
Trial registration: ClinicalTrials.gov NCT00343005.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Mitchell GH, Thomas AW, Margos G, Dluzewski AR, Bannister LH. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun. 2004;72:154–158.
- Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol. 2000;38:706–718.
- Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1994;67:59–68.
- Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ. Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem. 2001;276:31311–31320.
- Dutta S, Haynes JD, Moch JK, Barbosa A, Lanar DE. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A. 2003;100:12295–12300.
- Thomas AW, Deans JA, Mitchell GH, Alderson T, Cohen S. The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. Mol Biochem Parasitol. 1984;13:187–199.
- Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun. 1996;64:3310–3317.
- Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg. 1994;51:711–719.
- Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun. 2002;70:6948–6960.
- Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun. 2000;68:2899–2906.
- Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, et al. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun. 2002;70:6961–6967.
- Kocken CH, Narum DL, Massougbodji A, Ayivi B, Dubbeld MA, et al. Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Mol Biochem Parasitol. 2000;109:147–156.
- Polley SD, Conway DJ. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics. 2001;158:1505–1512.
- Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, et al. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun. 2003;71:1416–1426.
- Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun. 2005;73:3677–3685.
- Dicko A, Klion AD, Thera MA, Sagara I, Yalcouye D, et al. The etiology of severe anemia in a village and a periurban area in Mali. Blood. 2004;104:1198–1200.
- Trager W, Lanners HN. Initial extracellular development in vitro of merozoites of Plasmodium falciparum. J Protozool. 1984;31:562–567.
- Fay MP. Random marginal agreement coefficients: rethinking the adjustment for chance when measuring agreement. Biostatistics. 2005;6:171–180.
- Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24:19–28.
- Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine. 2003;21:3406–3412.
- Wykes MN, Zhou YH, Liu XQ, Good MF. Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. J Immunol. 2005;175:2510–2516.
- Wykes M, Good MF. Memory B cell responses and malaria. Parasite Immunol. 2006;28:31–34.
- Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine. 2005;23:4148–4157.
- Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am J Trop Med Hyg. 1999;61:865–868.
- Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336:86–91.
- Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004;364:1411–1420.
- Mullen GE, Giersing BK, Ajose-Popoola O, Davis HL, Kothe C, et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine. 2006;24:2497–2505.
- Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A. 2006;103:18243–18248.
Source: PubMed